JP2011522897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522897A5 JP2011522897A5 JP2011513647A JP2011513647A JP2011522897A5 JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5 JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5
- Authority
- JP
- Japan
- Prior art keywords
- phentermine
- cancer
- formulated
- kit
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 9
- 229960001277 Phentermine Hydrochloride Drugs 0.000 claims 7
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims 7
- 229960003562 Phentermine Drugs 0.000 claims 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N Phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 6
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 6
- 229960004394 topiramate Drugs 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 206010012601 Diabetes mellitus Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 235000020828 fasting Nutrition 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000037242 Cmax Effects 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 229940107161 Cholesterol Drugs 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 208000008125 Hypoalphalipoproteinemias Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 208000000509 Infertility Diseases 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 1
- 230000035888 Maximum plasma concentration Effects 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 208000003627 Muscular Dystrophy Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000000689 Peptic Esophagitis Diseases 0.000 claims 1
- 208000002787 Pregnancy Complications Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 claims 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000035852 Tmax Effects 0.000 claims 1
- 206010046766 Uterine cancer Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 201000008739 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000003010 gallbladder disease Diseases 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 231100000486 side effect Toxicity 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
Claims (9)
- 少なくとも30kg/m2のボディー・マス・インデックスおよび肥満症と関連する状態を有する対象において体重減少を達成する方法に使用するためのキットであって、該方法が漸増用量単位剤形を投与することを含み、該漸増用量単位剤形が、
(a)制御放出用に製剤化された23mgのトピラメート、および即時放出用に製剤化された3.75mgのフェンテルミンを含む第一剤形であって、2週間にわたって毎日対象に投与される第一剤形;ならびに
(b)制御放出用に製剤化された46mgのトピラメート、および即時放出用に製剤化された7.5mgのフェンテルミン、または
制御放出用に製剤化された92mgのトピラメート、および即時放出用に製剤化された15mgのフェンテルミンを含む第二剤形
を含み、制御放出用に製剤化されたトピラメートが投与後6〜10時間(Tmax)で最大血漿濃度(Cmax)に達し、非制御放出トピラメートよりも低いCmaxを示し、濃度時間曲線下面積(AUC)によって定義される総薬物曝露を減少させることなく、治療の有効性を損なうことなく副作用の減少を可能にし、かつ、
第二剤形が少なくとも2年にわたって毎日対象に投与され、それによって体重減少を達成し、肥満症と関連する状態を治療する、キット。 - フェンテルミンがフェンテルミン塩酸塩であり、第一剤形内のフェンテルミン塩酸塩の量が4.92mgであり、かつ、4.92mgのフェンテルミン塩酸塩が3.75mgのフェンテルミンを提供する、請求項1に記載のキット。
- フェンテルミンがフェンテルミン塩酸塩であり、第二剤形内のフェンテルミン塩酸塩の量が9.84mgであり、かつ、9.84mgのフェンテルミン塩酸塩が7.5mgのフェンテルミンを提供する、請求項1に記載のキット。
- 肥満症と関連する状態が糖尿病、空腹時血中グルコース上昇、インスリン抵抗性、耐糖能異常、肺高血圧症、喘息、息切れ、胆嚢疾患、脂質異常症、高コレステロール、高濃度のトリグリセリド、骨関節炎、逆流性食道炎、睡眠時無呼吸、月経不順、不妊症、妊娠合併症、痛風、高血圧、高血圧症、冠動脈疾患、心臓疾患、筋ジストロフィー、脳卒中、血栓脳卒中、深部静脈血栓症(DVT)、片頭痛、代謝障害、低αリポタンパク血症、家族性複合型高脂血症、シンドロームX、インスリン抵抗性シンドロームX、結腸癌、直腸癌、腎臓癌、食道癌、胆嚢癌、膵臓癌、前立腺癌、乳癌、子宮癌、卵巣癌、子宮内膜癌、および子宮頸癌からなる群から選択される、請求項1に記載のキット。
- 肥満症と関連する状態が高血圧、高濃度のトリグリセリド、空腹時血中グルコース上昇、および糖尿病からなる群から選択される、請求項1に記載のキット。
- 対象が高血圧、高濃度のトリグリセリド、空腹時血中グルコース上昇、および糖尿病からなる群から選択される少なくとも2つの肥満症と関連する状態に苦しんでいる、請求項1に記載のキット。
- 制御放出用に製剤化されたトピラメートが持続放出用、遅延放出用またはその両方用に製剤化されている、請求項1に記載のキット。
- 漸増用量単位剤形が経口投与用に製剤化されている、請求項1に記載のキット。
- 体重減少が、体重の少なくとも10%の減少を達成するのに有効である、請求項1に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/135,953 US20090304789A1 (en) | 2008-06-09 | 2008-06-09 | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US12/135,953 | 2008-06-09 | ||
PCT/US2009/046805 WO2009152190A1 (en) | 2008-06-09 | 2009-06-09 | Escalating dosing regimen for effecting weight loss and treating obesity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015102962A Division JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalatingdosingregimen) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011522897A JP2011522897A (ja) | 2011-08-04 |
JP2011522897A5 true JP2011522897A5 (ja) | 2013-11-14 |
JP5752595B2 JP5752595B2 (ja) | 2015-07-22 |
Family
ID=40863844
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
JP2011513647A Active JP5752595B2 (ja) | 2008-06-09 | 2009-06-09 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalatingdosingregimen) |
JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalatingdosingregimen) |
JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalating dosing regimen) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalatingdosingregimen) |
JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート/フェンテルミン組成物およびその使用方法 |
JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画(escalating dosing regimen) |
Country Status (18)
Country | Link |
---|---|
US (11) | US20090304789A1 (ja) |
EP (2) | EP2300002A1 (ja) |
JP (6) | JP2011522896A (ja) |
KR (3) | KR20110042280A (ja) |
CN (4) | CN102112127A (ja) |
AU (2) | AU2009257572C1 (ja) |
BR (2) | BRPI0914991A2 (ja) |
CA (2) | CA2727313C (ja) |
CL (2) | CL2010001366A1 (ja) |
CY (1) | CY1118103T1 (ja) |
DK (1) | DK2317997T3 (ja) |
ES (1) | ES2606041T3 (ja) |
HK (1) | HK1213489A1 (ja) |
IL (2) | IL209875A (ja) |
MX (2) | MX2010013503A (ja) |
PT (1) | PT2317997T (ja) |
WO (2) | WO2009152190A1 (ja) |
ZA (2) | ZA201008839B (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
BR112012016799A2 (pt) * | 2010-01-07 | 2019-10-08 | Vivus Inc | tratamento da síndrome de apneia obstrutiva do sono com uma combinação de um inibidor da anidrase carbônica e um agente ativo adicional |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR102012004888A2 (pt) * | 2012-03-05 | 2013-10-22 | Phartrials Pesquisas Farmaceuticas Ltda | Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas |
IN2012DE00826A (ja) * | 2012-03-21 | 2015-08-21 | Ranbaxy Lab Ltd | |
CN103316026B (zh) * | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
JP6055076B2 (ja) * | 2012-03-23 | 2016-12-27 | インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ | シネフリン及びトピラマートを含む組み合わせ製品 |
CN102579367B (zh) | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
BR102012026555B1 (pt) * | 2012-10-17 | 2022-10-04 | Phartrials Pesquisas Farmacêuticas Ltda | Processo de obtenção e composição de fármaco proveniente do quenodeoxicolato ligado a um derivado de sulfamato monossacarídeo natural d-frutose (topiramato) e a uma fenilcetona (bupropriona) para tratamento da obesidade e das síndromes plurimetabólicas |
US8652527B1 (en) * | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US20140294950A1 (en) * | 2013-03-15 | 2014-10-02 | Vivus, Inc. | Methods of treating obesity in responder and non-responder populations |
DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
US11278682B2 (en) | 2014-11-09 | 2022-03-22 | Sipnose Ltd. | Device and method for aerosolized delivery of substance to a natural orifice of the body |
US11116914B2 (en) | 2014-11-09 | 2021-09-14 | Sipnose Ltd. | Device and method for aerosolized delivering of substance to a natural orifice of the body |
US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
US11471618B2 (en) | 2014-11-09 | 2022-10-18 | Sipnose Ltd. | Adjustable dosing delivery and multi sectioned drug compartment |
AU2014331995B2 (en) * | 2013-10-08 | 2020-01-30 | Vivus, Inc. | Methods of preventing progression to type 2 diabetes mellitus |
US20150157672A1 (en) * | 2013-12-09 | 2015-06-11 | Phytology Labs, Inc. | Kits and methods for sustained weight loss |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
US10498398B2 (en) * | 2015-10-12 | 2019-12-03 | Walmart Apollo, Llc | Data synthesis using near field communication |
US20170319540A1 (en) * | 2016-05-06 | 2017-11-09 | Vivus, Inc. | Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis |
EP3897730A1 (en) * | 2018-12-18 | 2021-10-27 | DDP Specialty Electronic Materials US, Inc. | A sustained release composition comprising a methylcellulose |
CN109908165B (zh) * | 2019-04-26 | 2020-06-09 | 北京大学 | 一种含有雷公藤红素的组合物及其应用 |
CN109999044B (zh) * | 2019-05-24 | 2020-06-09 | 北京大学 | 一种含有醉茄素a的组合物及其应用 |
KR102199452B1 (ko) | 2019-10-17 | 2021-01-06 | 안지훈 | 퇴식처리장치 |
DE212021000392U1 (de) * | 2020-06-04 | 2023-06-23 | Sipnose Ltd. | Arzneimittelverabreichungsvorrichtungen zum Verabreichen von Substanzen in einen Körperhohlraum durch heterogene Aerolisierung zum Behandeln von Binge-Eating-Störungen und/oder Adipositas |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4895845A (en) * | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
US4792569A (en) * | 1987-08-27 | 1988-12-20 | Mcneilab, Inc. | Anticonvulsant phenethyl sulfamates |
US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
FR2684101B1 (fr) * | 1991-11-22 | 1993-12-31 | Adir Cie | Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
US5498629A (en) * | 1993-12-23 | 1996-03-12 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
RU2214241C2 (ru) * | 1996-06-28 | 2003-10-20 | Орто-Макнейл Фармасьютикал, Инк. | Способ лечения ожирения и способ индуцирования потери веса у млекопитающих |
US5753694A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
US5900418A (en) | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
US5990418A (en) * | 1997-07-29 | 1999-11-23 | International Business Machines Corporation | Hermetic CBGA/CCGA structure with thermal paste cooling |
US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
IL144406A0 (en) * | 1999-01-19 | 2002-05-23 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in treating cluster headaches |
DK1158973T3 (da) | 1999-02-24 | 2005-05-30 | Univ Cincinnati | Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser |
NZ514811A (en) * | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
MXPA01010221A (es) * | 1999-04-08 | 2002-03-27 | Johnson & Johnson | Derivados anticonvulsivos utiles para disminuir la presion sanguinea. |
US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
EP2305227B1 (en) * | 1999-06-14 | 2015-05-06 | Vivus, Inc. | Combination therapy for the treatment of diabetes associated with obesity |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US20080255093A1 (en) | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US7553818B2 (en) | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US7659256B2 (en) | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
AU2001280486A1 (en) * | 2000-07-07 | 2002-01-21 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x |
CA2417304A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
ATE334718T1 (de) * | 2000-10-30 | 2006-08-15 | Ortho Mcneil Pharm Inc | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln |
RU2317086C2 (ru) * | 2001-02-02 | 2008-02-20 | Орто-Макнейл Фармасьютикал, Инк. | Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина |
US20030072802A1 (en) * | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US7109198B2 (en) * | 2002-05-17 | 2006-09-19 | Duke University | Method for treating obesity |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
WO2005063206A1 (en) | 2003-12-23 | 2005-07-14 | Alza Corporation | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
KR20060128995A (ko) * | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
RU2007103313A (ru) | 2004-08-03 | 2008-09-10 | ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) | Комбинация бупропина и другого состава для эффективной потери веса |
ES2325773T5 (es) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
EA015012B1 (ru) | 2004-12-23 | 2011-04-29 | Арена Фармасьютикалз, Инк. | Композиция, содержащая фентермин и избирательный агонист рецептора 5ht, и ее применение |
WO2006124506A2 (en) | 2005-05-13 | 2006-11-23 | Abbott Laboratories | Combination and use of drugs |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
WO2007084290A2 (en) | 2006-01-12 | 2007-07-26 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain |
US9744137B2 (en) | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
FR2907550B1 (fr) | 2006-10-18 | 2009-01-16 | Renault Sas | Ligne de prelevement de gaz circulant dans un conduit de moteur a combustion interne et banc d'essais comportant une telle ligne |
TWI504419B (zh) | 2006-11-09 | 2015-10-21 | Orexigen Therapeutics Inc | 層狀醫藥調配物 |
EP1973528B1 (en) * | 2006-11-17 | 2012-11-07 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
WO2009061436A1 (en) | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
BR112012016799A2 (pt) | 2010-01-07 | 2019-10-08 | Vivus Inc | tratamento da síndrome de apneia obstrutiva do sono com uma combinação de um inibidor da anidrase carbônica e um agente ativo adicional |
-
2008
- 2008-06-09 US US12/135,953 patent/US20090304789A1/en not_active Abandoned
-
2009
- 2009-06-09 KR KR1020117000416A patent/KR20110042280A/ko active Search and Examination
- 2009-06-09 US US12/481,548 patent/US8580299B2/en active Active
- 2009-06-09 CA CA2727313A patent/CA2727313C/en active Active
- 2009-06-09 AU AU2009257572A patent/AU2009257572C1/en active Active
- 2009-06-09 JP JP2011513646A patent/JP2011522896A/ja active Pending
- 2009-06-09 CN CN2009801304444A patent/CN102112127A/zh active Pending
- 2009-06-09 KR KR1020117000417A patent/KR20110044847A/ko active Application Filing
- 2009-06-09 CN CN201510977746.2A patent/CN105534921A/zh active Pending
- 2009-06-09 KR KR1020147027268A patent/KR20140121491A/ko not_active Application Discontinuation
- 2009-06-09 CN CN201510112539.0A patent/CN104825477A/zh active Pending
- 2009-06-09 ES ES09763479.4T patent/ES2606041T3/es active Active
- 2009-06-09 PT PT97634794T patent/PT2317997T/pt unknown
- 2009-06-09 CN CN2009801303795A patent/CN102112126A/zh active Pending
- 2009-06-09 AU AU2009257573A patent/AU2009257573B2/en active Active
- 2009-06-09 BR BRPI0914991A patent/BRPI0914991A2/pt not_active Application Discontinuation
- 2009-06-09 DK DK09763479.4T patent/DK2317997T3/en active
- 2009-06-09 MX MX2010013503A patent/MX2010013503A/es active IP Right Grant
- 2009-06-09 EP EP09763480A patent/EP2300002A1/en not_active Ceased
- 2009-06-09 CA CA2727319A patent/CA2727319C/en active Active
- 2009-06-09 JP JP2011513647A patent/JP5752595B2/ja active Active
- 2009-06-09 EP EP09763479.4A patent/EP2317997B1/en active Active
- 2009-06-09 WO PCT/US2009/046805 patent/WO2009152190A1/en active Application Filing
- 2009-06-09 BR BRPI0914985-6A patent/BRPI0914985B1/pt active IP Right Grant
- 2009-06-09 WO PCT/US2009/046804 patent/WO2009152189A1/en active Application Filing
- 2009-06-09 MX MX2010013505A patent/MX342684B/es active IP Right Grant
-
2010
- 2010-12-07 CL CL2010001366A patent/CL2010001366A1/es unknown
- 2010-12-07 CL CL2010001365A patent/CL2010001365A1/es unknown
- 2010-12-08 ZA ZA2010/08839A patent/ZA201008839B/en unknown
- 2010-12-08 ZA ZA2010/08840A patent/ZA201008840B/en unknown
- 2010-12-09 IL IL209875A patent/IL209875A/en active IP Right Grant
- 2010-12-09 IL IL209874A patent/IL209874B/en active IP Right Grant
-
2013
- 2013-10-08 US US14/048,416 patent/US8895057B2/en active Active
-
2014
- 2014-09-24 US US14/495,250 patent/US9011906B2/en active Active
-
2015
- 2015-04-06 US US14/679,754 patent/US20150209325A1/en not_active Abandoned
- 2015-05-20 JP JP2015102962A patent/JP6077053B2/ja active Active
- 2015-07-30 JP JP2015151088A patent/JP2016006085A/ja active Pending
- 2015-10-08 US US14/878,235 patent/US20160022630A1/en not_active Abandoned
-
2016
- 2016-02-12 HK HK16101537.0A patent/HK1213489A1/zh unknown
- 2016-05-10 US US15/150,907 patent/US20160250180A1/en not_active Abandoned
- 2016-10-19 CY CY20161101053T patent/CY1118103T1/el unknown
- 2016-12-20 JP JP2016246871A patent/JP6214750B2/ja active Active
-
2017
- 2017-01-11 JP JP2017002448A patent/JP2017105788A/ja active Pending
-
2018
- 2018-12-14 US US16/220,276 patent/US20190350897A1/en not_active Abandoned
-
2020
- 2020-02-20 US US16/796,194 patent/US20200188352A1/en not_active Abandoned
-
2021
- 2021-08-23 US US17/408,881 patent/US20210379013A1/en not_active Abandoned
-
2023
- 2023-03-22 US US18/124,774 patent/US20230233521A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011522897A5 (ja) | ||
EP2317997B1 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
US20200188313A1 (en) | Low dose topiramate/phentermine composition and methods of use thereof | |
JP2010514829A5 (ja) | ||
JP2009542699A5 (ja) | ||
JP2012520866A5 (ja) | ||
JP2009542702A5 (ja) | ||
JP2012006970A5 (ja) | ||
JP2009533356A5 (ja) | ||
JP2011527333A5 (ja) | ||
JP2008515905A5 (ja) | ||
EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
JP2015526458A5 (ja) | ||
JP2008509224A5 (ja) | ||
JP2008526950A5 (ja) | ||
JP2009506043A5 (ja) | ||
JP2010540519A5 (ja) | ||
JP2023116697A5 (ja) | ||
JP2010515682A5 (ja) | ||
JP2008543853A5 (ja) | ||
JP2011157375A5 (ja) | ||
WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
CN102319208A (zh) | 一种治疗化放疗所致口腔黏膜炎的悬浮液组合物 | |
JP2013511287A5 (ja) | ||
JP2013503908A5 (ja) |